Comments
Transcript
Bioindustry Park and Start-ups - Ceris-CNR
Per tornare allo sviluppo Silvano Fumero XXX Convegno di economia e politica industriale Moncalieri 22-23 settembre 2006 The “red biotech” paradigm Source Burril & Co - 2005 Biotech evolution model Academia Seed Capital Venture Capital B B B Res. Res. Res. Mkt Dev. 1980 Mkt Dev. 2000 Mkt Dev. 2020 The R&D Process - Time and Money Lead Candidate Discovery Years Cost (%) 5.5 19% Development Pre-Clinical 1.0 10% NDA Clinical Development PI P II P III FDA Approval 1.5 2.0 2.5 1.5 15% 22% 31% 3% Source: McKinsey & Co, Lehman Brothers, PhRMA, FDA 14.0 100% Payments typically take the form of upfront payments once a deal is closed and milestone payments contingent upon clearing pre-specified development hurdles Preclinical Phase I Phase II Phase III Upfront ($ millions) 2 5 10 15 Milestones ($ millions) 15 25 35 50 7 10 20 25 Royalty (percentage) Nature Review/ Drug Discovery 2003 (Million Dollars) Mc Kinsey Analysis of deals 1991-2002 CREABILIS therapeutics s.r.l. Via Ribes, 5 – Bioindustry Park del Canavese 10010 Colleretto Giacosa (TO) – ITALY Ph. +39 0125 53543 – fax +39 0125 538897 http://www.creabilistherapeutics.com [email protected] THE MISSION CREABILIS Therapeutics is a drug discovery and development biotech company, founded in May 2003, privately funded, located in the Bioindustry Park (Colleretto Giacosa, TORINO) with the aim to discover, select, develop and bring to commercial fruition novel and highly innovative therapeutic agents. Products - Targets - Clinical Indications CT327 Psoriasis TrKA TNF Pathologies Behçet Disease CT335 336 Kinases CT500s RAGE TLR HMGB1 Inflammation Sepsis Tumor CNS Path. Atherosclerosis CT400s CT319 Tat AIDS BASIC SCIENCE, TECHNOLOGIES AND DRUGABILITY SMALL MOLECULES MINIPEGYLATION (Pegylation with low MW PEG) PROTEINS Rational Evolution Technology (Nautilus) NUCLEIC ACIDS Bent DNA/PNA Chimera / hybrids PEPTIDES Chem. Modific. CT327 Topical Psoriasis CT335/336 Systemic Treat. Orphan Drug Application CT500s HMGB1/RAGE Pathologies CT400s HMGB1 Pathologies CT319 AIDS CT Pipeline From scientific result to company creation: basic assets GOOD SCIENCE INTELLECTUAL PROPERTY CAPITAL MANAGEMENT © Bioindustry Park del Canavese SpA - 2066 www.bioindustrypark.it - www.eporgen.com 14 © Bioindustry Park del Canavese SpA - 2066 www.bioindustrypark.it - www.eporgen.com 15 Bioindustry Park Canavese Eporgen Venture Progetto Discovery The Eporgen Venture model •“Seed-capital” company founded and funded by non institutional investors; •The shareholders of Eporgen Venture are private investors residents in the area of Ivrea, Turin and Biella. All of them have been motivated from the desire to create and support a series of initiatives aiming to promote new companies (start-up) based on highly innovative projects with international scientific relevance; •Eporgen Venture SpA has the institutional objective of finding proposals from Italian or foreign researchers, either from academic or private institutions, evaluate their potential and give them the means to develop and bring their projects, in a time frame of 2-3 years, to a level where the results can be proposed to new investors and Venture Capital or generate partnerships with medium-large pharma/biotech companies. Bioindustry Park and Start-ups: Bioincubation and DISCOVERY 1 project –steps and quantitative results Bioindustry Park Canavese Eporgen Venture Involvement of local investors 5 5 Availability of 3 Ml euro for investment in start-ups www.bioindustrypark.it - www.eporgen.com © Bioindustry Park del Canavese SpA - 2066 Phisical incubator Supporting programmes 18 Discovery incubator: first start-ups 1) TARGET HEART Torino, Roma 2) SPIDER BIOTECH Siena 3) NARVALUS Padova, Rovereto 5) BIO NUCLEON Napoli © Bioindustry Park del Canavese SpA - 2005 4) BIOPAINT Ivrea, Bologna, Viterbo, Trieste www.bioindustrypark.i 19 t IL CLUSTER BIOTECH DEL BIOINDUSTRY PARK: CNR CREABILIS THER. LABORATORIO INTEGRATO METODOLOGIE AVANZATE UNIV. TO BIOMAN AETHIA HMGBiotech BRACCO A.A.A. RBM / SERONO 1) TARGET HEART 2) SPIDER BIOTECH MEDESTEA RESEARCH 3) NARVALUS 4) BIOPAINT 5) BIO NUCLEON BIOLAB CHEMSAFE SITEC CONS EPORGEN VENTURE COLGITEC BIO3 RESEARCH